Innovative pro-drug delivers superior efficacy with improved drug-like properties and safety profile

InspectIR Systems, a medical technology company focused on point-of-care diagnostics, today announced the successful completion of its Phase I study evaluating the performance of the company's point-of-care breathalyzer technology.

Lead cancer drug candidate, ST-001 nanoFenretinide, has received Institutional Review Board ("IRB") approval for its upcoming clinical trials for T-Cell Lymphomas.

OMO-103 in Phase 1b clinical trial

The Contract Manufacturing Agreement Will Provide the Clinical Supply of ST-001, SciTech's Lead Drug Candidate for Cancer

This is the new fantasy creature from the Phantasticals campaign that Ferrer has relaunched, coinciding with Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, on June 21. The aim is to raise public awareness of this rare, neurodegenerative, progressive disease that affects the motor neurons in the brain. Ferrer is leading the ADORE Phase III clinical trial to evaluate the safety and efficacy of the investigational drug FNP122 in the treatment of ALS.

This Brain Cancer Awareness Month (May), a handful of the brightest and best minds in brain cancer research will meet all around the US to discuss advances in treatment protocols for glioblastoma (GBM)

Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome.

Biosimilar Solutions, Inc. will set up a facility in Aguadilla in OcyonBio's Campus in Puerto Rico to support the production of BSC0826.

LTO Network announces that through its collaboration with integrator Sphereon, it will host the world's next generation of eClinical data. Triall will integrate its blockchain APIs with the eClinical solutions of CDS, realizing the world's first end-to-end eClinical platform powered by blockchain.

Novel NRCT-101SR shown in previous human studies to be effective and well-tolerated with no side effects

First Treatments for Patients with Rare Conditions Proven to Work

This trial marks the first step taken by Actipulse Neuroscience to use a new method of neuromodulation to stop or slow Alzheimer's disease, an issue that fails to be solved by anything currently available on the market

Triall will use LTO Network's blockchain infrastructure to anchor COVID-19 research data, enhancing the safety, security and reliability of research data in the digital era.

Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio's Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.

Presentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.

SEP361-203 study evaluating an investigational medication in people with Parkinson's disease experiencing Hallucinations and Delusions

Changes will foster research and innovation in the organization's next chapter

Unique solution offers sponsors a streamlined approach to the global supply chain

ISO 13485 certification is the first step in demonstrating conformance with European regulatory requirements and is mandatory to allow entry of Spinal Singularity products into the European community.

Food Allergy Research & Education's Collaborative to Advance Food Allergy Research and Care Continues to Grow; Food Allergy Medical Claims Up 75 percent in Wisconsin and 146 percent in Georgia since 2009

MedTech Strategist Innovation Summit, Nov. 27-28, at the Hyatt Regency San Francisco Airport, Burlingame, CA

Call For Paper - Submit By October 25, 2018

Tutera Medical announces its launch of Viveve® Solutions to its patients.

Open invitation to the Biopharma Industry as Almac's experts continue to showcase expertise

Food Allergy Research & Education's Collaborative to Advance Food Allergy Research Continues to Grow

New online tool connects cutting edge researchers with patients to advance food allergy research

The Roxbury Institute's Dr. Jaime Schwartz is the Principal Investigator in a New Breast Implant Study Now Recruiting Patients